{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-25-000161","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.885010+00:00","generated_at":"2026-05-16T15:55:04.177458+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application","bullets":["Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.","Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.","CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.","Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.","XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-25-000161","json":"https://secwatch.observer/filing/0001867096-25-000161.json","markdown":"https://secwatch.observer/filing/0001867096-25-000161.md","text":"https://secwatch.observer/filing/0001867096-25-000161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/0001867096-25-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/xers-20251201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:55:04.177458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}